# OnCo record siopel-3 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/siopel-3/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "siopel-3", "NCT00003912" ;
  schema:name "SIOPEL-3"@en ;
  schema:alternateName "SIOPEL 3"@en, "SIOPEL3"@en, "SIOP-SIOPEL-3"@en ;
  schema:description "SIOPEL-3 showed that children with standard-risk hepatoblastoma can be cured with cisplatin alone before and after surgery, leaving out doxorubicin and its heart damage, because the cure rate was the same as with the two-drug combination."@en ;
  schema:url <https://onco.cc/trials/siopel-3/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00003912> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/hepatoblastoma/>, <https://onco.cc/cancers/childhood-cancers/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/doxorubicin/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-siopel-3-cisplatin-vs-plado-standard-risk-hepatoblastoma-perilongo-nejm-2009/> .